TMEM16A on Qube 384

雑誌名: Ion Channel Modulation Symposium 2017
View file
著者: Joseph G. McGivern*, John K. Sullivan*, Kathryn A. Henckels*, Paul Wang*, David Powers*, Daniel Sauter**, Lars Løjkner**, Rasmus Jakobsen**, Mads Korsgaard**

TMEM16A (ANO1) is a Ca2+-activated Cl- channel (CaCC) that is involved in a plethora of physiological and pathophysiological conditions. The channel was suggested as a target for treatment of asthma, secretory diarrheas, and hypertension. TMEM16A is unique as its gating synergistically depends on voltage and cytosolic Ca2+ (Scudieri et al. 2012).
A robust and high-throughput electrophysiology assay for TMEM16A was long awaited, but progress was hampered by the fact that many automated patch clamp devices rely on the use of fluoride (F)in the internal solution to promote seal formation. However CaF2 has very low solubility and the resulting precipitation limits the ability to control precisely the concentration of Ca+ in the internal solution.
We recently developed a novel approach to test the pharmacological inhibition of TMEM16A on Qube with following characteristics:


• Consistently high success rates (>80%)
• Low run down
• High degree of pharmacological reproducibility (consistent IC50 values of multiple runs)